References
- Northrup H, Krueger DA. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013;49(4):243–54. doi:10.1016/j.pediatrneurol.2013.08.001.
- Isaacs H. Fetal and neonatal cardiac tumors. 2004;25(3):252–73. doi:10.1007/s00246-003-0590-4.
- Okmen F, Ekici H, Hortu I, et al. Outcomes of antenatally diagnosed fetal cardiac tumors: a 10-year experience at a single tertiary referral center. J Matern Neonatal Med. 2020. doi:10.1080/14767058.2020.1822316.
- Saffari A, Brösse I, Wiemer-Kruel A, Wilken B, Kreuzaler P, Hahn A, Bernhard MK, van Tilburg CM, Hoffmann GF, Gorenflo M, et al. Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age - a multicenter retrospective study. Orphanet J Rare Dis. 2019;14(1):1–13. doi:10.1186/s13023-019-1077-6.
- Nir-David Y, Brosilow S, Khoury A. Rapid response of a cardiac rhabdomyoma causing severe right ventricular outflow obstruction to Sirolimus in an infant with negative genetics for Tuberous sclerosis. Cardiol Young. 2021;31(2):312–4. doi:10.1017/S1047951120003819.
- Barnes BT, Procaccini D, Crino J, Blakemore K, Sekar P, Sagaser KG, Jelin AC, Gaur L. Maternal sirolimus therapy for fetal cardiac rhabdomyomas. N Engl J Med. 2018;378(19):1844–5. doi:10.1056/NEJMc1800352.
- Vachon-Marceau C, Guerra V, Jaeggi E, Chau V, Ryan G, Van Mieghem T. In-utero treatment of large symptomatic rhabdomyoma with sirolimus. Ultrasound Obstet Gynecol. 2019;53(3):420–1. doi:10.1002/uog.20196.
- Park H, Chang CS, Choi SJ, Young OS, Roh CR. Sirolimus therapy for fetal cardiac rhabdomyoma in a pregnant woman with tuberous sclerosis. Obstet Gynecol Sci. 2019;62(4):280–4. doi:10.5468/ogs.2019.62.4.280.
- Pluym ID, Sklansky M, Wu JY, Afshar Y, Holliman K, Devore GR, Walden A, Platt LD, Krakow D. Fetal cardiac rhabdomyomas treated with maternal sirolimus. Prenat Diagn. 2020;40(3):358–64. doi:10.1002/pd.5613.
- Oppenheimer F, Alonso A, Arias M, et al. Handling sirolimus in clinical practice. Nefrologia. 2006;26(2):64–93.
- Chu SH, Liu KL, Chiang YJ, Wang HH, Lai PC. Sirolimus used during pregnancy in a living related renal transplant recipient: a case report. Transplant Proc. 2008;40(7):2446–8. doi:10.1016/j.transproceed.2008.06.015.
- Jankowska I, Oldakowska-Jedynak U, Jabiry-Zieniewicz Z, Cyganek A, Pawlowska J, Teisseyre M, Kalicinski P, Markiewicz M, Paczek L, Socha J, et al. Absence of teratogenicity of sirolimus used during early pregnancy in a liver transplant recipient. Transplant Proc. 2004;36(10):3232–3. doi:10.1016/j.transproceed.2004.11.102.
- Veroux M, Corona D, Veroux P. Pregnancy under everolimus-based immunosuppression. Transpl Int. 2011;24(12):115–7. doi:10.1111/j.1432-2277.2011.01356.x.
- Framarino Dei Malatesta M, Corona LE, De Luca L, Rocca B, Manzia TM, Orlando G, Tisone G, Iaria G. Successful pregnancy in a living-related kidney transplant recipient who received sirolimus throughout the whole gestation. Transplantation. 2011;91(9):e69–71. doi:10.1097/TP.0b013e3182154267.
- Wang C, Li X, Peng L, Gou X, Fan J. An update on recent developments in rupture of renal angiomyolipoma. Med (United States). 2018;97(16). doi:10.1097/MD.0000000000010497.
- Zapardiel I, Delafuente-Valero J, Bajo-Arenas JM. Renal angiomyolipoma during pregnancy: Review of the literature. Gynecol Obstet Invest. 2011;72(4):217–9. doi:10.1159/000329328.